BioNTech
 BioNTech    | |
|---|---|
 | |
| Founder | • Christoph Huber • Ugur Sahin • Özlem Türeci |
BioNTech is a German biotechnology company dedicated to the development and manufacture of active immunotherapies for a patient-specific approach to the treatment of serious diseases.[1]
Turkish founders
Founded in 2008 by Turkish married scientists Özlem Türeci and Ugur Sahin and the Austrian oncologist Christoph Huber, the company originally set out to develop new types of immunotherapy against cancer, modifying patients’ T cells to target cancer-specific antigens. It researches drugs based on messenger RNA (mRNA) for use as individualised cancer immunotherapies, as vaccines against infectious diseases and as protein replacement therapies for rare diseases, and also engineered cell therapy, novel antibodies and small molecule immunomodulators as treatment options for cancer.
BioNTech developed an mRNA-based human therapeutic for intravenous administration, to bring individualised mRNA-based cancer immunotherapy to clinical trials and to establish its own manufacturing process.[2]
COVID-19 vaccine
The company’s shares shot up 23.4% on Monday morning after the COVID-19 vaccine it is developing with the US pharma giant Pfizer became the first candidate worldwide to show positive results in phase 3 trials, the crucial final stage of testing.
The total value of BioNTech’s stock is currently $21.9bn (£16.6bn), more than four times that of German national carrier Lufthansa and a triumph for a company that only made its debut on the US stock market a year ago.[3]
References
This page imported content from Wikipedia on 9 November 2020.Wikipedia is not affiliated with Wikispooks. Original page source here
